Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
• this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
• bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens.
• Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity.
• the compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.
• Gram-positive pathogens for example Staphylococci, Enterococci, Streptococci and mycobacteria
• Staphylococci Enterococci
• Streptococci mycobacteria
• MRSA methicillin resistant staphylococcus aureus
• MRCNS methicillin resistant coagulase negative staphylococci
• penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium.
• Gram-positive pathogens is vancomycin.
• Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity.
• antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.
• agents such as ⁇ -lactams, quinolones and macro lides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H.influenzae and M.catarrhalis. Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.
• DNA gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA.
• ATP adenosine triphosphate
• DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA.
• the enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A 2 B 2 tetrameric complex.
• the A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage.
• the B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.
• topoisomerase IV Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).
• DNA gyrase is a well-validated target of antibacterials, including the quinolones and the coumarins.
• the quinolones e.g. ciprofloxacin
• ciprofloxacin are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol. Rev. 61: 377-392).
• Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species.
• quinolones are successful antibacterials, resistance generated primarily by mutations in the target (DNA gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C, 2002, The Lancet Infectious Diseases 2: 530-538).
• quinolones as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364).
• cardiotoxicity as predicted by prolongation of the QT 0 interval, has been cited as a toxicity concern for quinolones.
• cyclothialidines Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis (Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).
• Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomeraseIV are known in the art.
• coumarin-containing compounds are described in patent application number WO 99/35155
• 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879
• pyrazole compounds are described in patent application WO 01/52845 (US patent US6,608,087).
• R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy,
• R 3 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C ⁇ alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 3 may be optionally substituted on carbon by one or more halo or C 3-6 Cy cloalkyl; R 4 and R 5 are independently selected from hydrogen or C 1-4 alkyl; X is a direct bond, -CH 2 -, -C(O)- or S(O) q - (wherein q is 1 or 2); Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ; R 6 is a substituent on carbon and is selected from halo, nitro, cyano,
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-, -C(O)-, -N(R 17 )C(O)-, -C(O)N(R 18 )-, -S(O) P -, -SO 2 N(R 19 )- or -N(R 20 )SO 2 -; wherein R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or C 1 - 4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, TV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N, iV-dimethylcarbamoyl, A ⁇ iV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethyl
• R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, Ci -4 alkoxy,
• R 3 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C2-4alkenyl, C 2-4 alkynyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 3 may be optionally substituted on carbon by one or more halo or C 3-6 cycloalkyl;
• R 4 and R 5 are independently selected from hydrogen or C 1-4 alkyl
• Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, Ci -4 alkanoyloxy, N-(C 1-4 alkyl)amino, ⁇ iV-(Ci- 4 alkyl) 2 amino, C 1-4 al
• R 6 may be optionally substituted on carbon by one or more R 10 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 11 ; m is 0-4; wherein the values of R 6 may be the same or different;
• R 10 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C ⁇ alkoxy, Ci -4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(Ci -4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, Ci -4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, N, N-(C 1-4 alkyl) 2 sulphamoyl, C 1-4 alkylsulphon
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-, -C(O)-, -N(R 17 )C(O)-, -C(O)N(R 18 )-, -S(0) p -, -SO 2 N(R 19 )- or -N(R 20 )SO 2 -; wherein R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl,
• N iV-dimethylcarbamoyl, N,iV ⁇ diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, ⁇ N-dimethylsulphamoyl, N, TV-diethylsulphamoyl or iV-methyl-iV-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
• R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy,
• R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl
• R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 alkanoyl, Ci -4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 2 may be optionally substituted on carbon by one or more halo or C 3 . 6 cycloalkyl;
• R 3 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 alkanoyl, Ci -4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 3 may be optionally substituted on carbon by one or more halo or C 3-6 cycloalkyl; R 5 is hydrogen or C 1-4 alkyl; Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, iV-hydroxyformamido, hydrazinocarbonyl, iV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, Ci- 4 alkanoyloxy, iV-(Ci..
• R 10 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Cj-4alkanoyl, Ci-4alkanoyloxy, N-(Ci- 4 alkyl)amino, ⁇ -/V-(Ci- 4 alkyl) 2 amino, C 1-4 alkanoylamino, iV-(C 1-4 alkyl)carbamoyl, A ⁇ JV-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, N, N-(C i _ 4 alky l) 2 sulphamoy 1, C i ⁇ alkylsulphonylamino, C i -4 alkoxycarbony
• R 7 , R 11 and R 15 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, Ci -4 alkylsulphonyl, C] -4 alkoxycarbonyl, carbamoyl, JV-(Cj. 4 alkyl)carbamoyl, ⁇ N-(Ci -4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-, -C(O)-, -N(R 17 )C(O)-, -C(O)N(R 18 )-, -S(O) P -, -SO 2 N(R 19 )- or -N(R 20 )SO 2 -; wherein R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, 7V-methylcarbamoyl, iV-ethylcarbamoyl, N,iV-dimethylcarbamoyl, A ⁇ iV-diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsul
• R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy,
• R 3 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 2- 4alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 3 may be optionally substituted on carbon by one or more halo or C 3-6 Cy cloalkyl;
• Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, iV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Ci -4 alkyl, C 2 - 4 alkenyl, C 2-4 alkynyl, Ci -4 alkoxy, C 1-4 alkanoyl, Ci -4 alkanoyloxy, JV-(C 1-4 alkyi)amino, JV,N ⁇ (Ci -4 alkyl) 2 amino, C 1-4 alkanoylamino, iV-(C 1-4 alkyl)carbamoyl, ⁇ N-(C 1-4 alkyl)2carbamoyl
• R 6 may be optionally substituted on carbon by one or more R 10 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 11 ; in is 0-4; wherein the values of R 6 may be the same or different;
• R 10 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C ⁇ alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1 . 4 alkyl) 2 amino,
• R 7 , R 11 and R 15 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, N, N-(C i -4 alky ⁇ carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-,
• R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or Ci -4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, ⁇ N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl,
• R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, Q ⁇ alkoxy, C 2 . 4 alkenyl, C 2-4 alkynyl, Ci- 4 alkanoyl, Ci-4alkylS(O) a wherein a is 0 to 2 and C3.6cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl;
• R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, C 1-4 alkoxy, C 2 - 4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 2 may be optionally substituted on carbon by one or more halo or C 3-6 cycloalkyl; R 3 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, Q ⁇ alkoxy,
• Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, iV-hydroxyformamido, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci.
• C 1-4 alkylsulphonyl C 1-4 alkoxycarbonyl, carbamoyl, iV-(C 1-4 alkyl)carbamoyl, ⁇ N-(C 1-4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-, -C(O)-, -N(R 17 )C(O)-, -C(O)N(R 18 )-, -S(O) P -, -SO 2 N(R 19 )- or -N(R 20 )SO 2 -; wherein R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N, JV-dimethylcarbamoyl, ⁇ iV-diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphin
• the invention also provides a compound which is
• the invention also provides a pharmaceutical composition that comprises a compound of formula I, IA, IB, IC, or ID or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
• the invention also provides a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or ID, or a pharmaceutically-acceptable salt thereof.
• the invention also provides a method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or ID, or a pharmaceutically acceptable salt.
• the invention also provides a compound of formula I, IA, IB, IC, or ID, and pharmaceutically acceptable salts thereof for use as a medicament.
• the invention also provides the use of a compound of formula I, IA, IB, IC, or ID, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
• the invention also provides the use of a compound of formula I, IA, IB, IC, or ID, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
• the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated): Process a) converting a compound of formula (II):
• D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.
• L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-l-yloxy.
• M is an organometallic group
• suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro.
• alkyl includes both straight and branched chain alkyl groups.
• C 1-4 alkyl includes methyl, ethyl, propyl, isopropyl and t-butyl.
• references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.
• a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring nitrogen and / or a ring sulphur atom may be optionally oxidised to form the N- or S-oxide(s).
• a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
• a “heterocyclyl” is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen.
• heterocyclyl examples and suitable values of the term "heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, JV-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-W-oxide and quinoline-JV-oxide.
• a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
• Suitable values for "carbocyclyl” include cyclopropyl, cyclobutyl, 1 -oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
• a particular example of “carbocyclyl” is phenyl.
• An example of "Ci ⁇ alkanoyloxy” is acetoxy.
• Examples of "C 1-4 alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
• Examples of include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino.
• Examples of “C 1-4 alkoxy” include methoxy, ethoxy and propoxy.
• Examples of “Cmalkanoylamino” include formamido, acetamido and propionylamino.
• Examples of "Ci -4 alkylS(O) a wherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
• Examples of “C 1-4 alkanoyl” include propionyl and acetyl.
• Examples of 'W-(C 1 _ 4 alkyl)amino include methylamino and ethylamino.
• Examples of " ⁇ N-(C 1-4 alkyl)2amino” include di-iV-methylamino, di-(W-ethyl)amino and W-ethyl-W-methylaniino.
• Examples of "C 2-4 alkenyl” are vinyl, allyl and 1-propenyl.
• Examples of “C 2-4 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
• Examples of "iV-(C 1-4 alkyl)sulphamoyl” are W-(methyl)sulpharnoyl and W-(ethyl)sulphamoyl.
• Examples of "7V,iV-(Ci -4 alkyl)2Sulphamoyl” are N,W-(dimethyl)sulphamoyl and iV-(methyl)-iV-(ethyl)sulphamoyl.
• Examples of 'W-(C 1-4 alkyl)carbamoyl are methylaminocarbonyl and ethylaminocarbonyl.
• Examples of "WiV-(C 1 -4 alkyl) 2 carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl.
• Examples of "JV-(C i -4 alkoxy)carbamoyl” are methoxyaminocarbonyl and isopropoxyaminocarbonyl.
• Examples of 'W-(C 1-4 alkyl)-N-(C 1-4 alkoxy)carbamoyl” are W-methyl-W- methoxyaminocarbonyl and Wmethyl-iV-ethoxyaminocarbonyl.
• C 3-6 cycloalkyl are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl.
• Examples of 'W-(Cj - 4 alkyl)ureido" are JV'-methylureido and W-isopropylureido.
• Examples of U N',N'-(C ⁇ -4 alkyl) 2 ureido" are N 1 N'- dimethylureido and W-methyl-W-isopropylureido. Examples of
• 'W-(Ci-4alkyl)hydrazinocarbonyP' are N'-methylhydrazinocarbonyl and JV'- isopropylhydrazinocarbonyl.
• Examples of 'W'W'-(C 1- 4alkyl) 2 hydrazinocarbonyl" are N 1 N'- dimethylhydrazinocarbonyl and W-methylW-isopropylhydrazinocarbonyl.
• Examples of "Cmalkylsulphonylamino” include methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino.
• C 1-4 alkylsulphonylaminocarbonyl examples include methylsulphonylaniinocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl.
• Examples of “C 1-4 alkylsulphonyl” include methylsulphonyl, isopropylsulphonyl and /-butylsulphonyl.
• a compound of formula (I) may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.
• Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, ⁇ -glycerophosphate. fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid.
• suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, iV-methylpiperidine, iV-ethylpiperidine, procaine, dibenzylamine, ⁇ iV-dibenzylethylamine, tris-(2-hydroxyethyl)amine, TV-methyl d-glucamine and amino acids such as lysine.
• a preferred pharmaceutically-acceptable salt is the sodium salt.
• salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.
• a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
• the formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names.
• the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the inhibition of DNA gyrase by the standard tests described hereinafter.
• R 1 is selected from C 1-4 alkyl.
• R 1 is selected from methyl.
• R 2 is selected from halo.
• R 2 is selected from fluoro, chloro or bromo.
• R 2 is selected from chloro or bromo.
• R 3 is selected from hydrogen or halo.
• R 3 is selected from hydrogen, fluoro or chloro.
• R 3 is selected from hydrogen or chloro.
• R and R are both selected from chloro.
• R 4 and R 5 are both hydrogen.
• X is a direct bond
• X is -CH 2 -.
• X is -C(O)-.
• X is S(O)q- (wherein q is 1 or 2).
• Ring A is carbocyclyl.
• Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 .
• Ring A is heterocyclyl. Ring A is pyridinyl, benzothiazolyl, quinolinyl, pyrimidinyl or thiazolyl. Ring A is pyrimidinyl or thiazolyl. Ring A is pyrimidin-4-yl or thiazol-2-yl.
• R 6 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, N-(C 1 -4 alkoxy)carbamoyl or Ci -4 alkoxycarbonyl.
• R 6 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, iV-(methoxy)carbamoyl or methoxycarbonyl. m is 1 or 2; wherein the values of R 6 may be the same or different.
• R 1 is selected from C 1-4 alkyl;
• R 2 is selected from halo;
• R 3 is selected from hydrogen or halo;
• R 4 and R 5 are both hydrogen;
• X is a direct bond; Ring A is heterocyclyl;
• R 6 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, N-(C 1-4 alkoxy)carbamoyl or C 1-4 alkoxycarbonyl; and m is 1 or 2; wherein the values of R 6 may be the same or different; or a pharmaceutically acceptable salt thereof.
• R 2 is selected from chloro or bromo
• R 3 is selected from hydrogen or chloro
• R 4 and R 5 are both hydrogen
• X is a direct bond
• Ring A is pyrimidin-4-yl or thiazol-2-yl
• R 6 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, iV-(methoxy)carbarnoyl or methoxycarbonyl; m is 1 or 2; wherein the values of R 6 may be the same or different; or a pharmaceutically acceptable salt thereof.
• R 1 is selected from hydrogen, halo, or C 1-4 alkyl
• R 2 is selected from hydrogen, halo, or C 1-4 alkyl
• R 3 is selected from hydrogen, halo, or C ⁇ alkyl
• R 4 and R 5 are independently selected from hydrogen or C 1-4 alkyl
• Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, iV-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C h alky 1, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, JV-(Ci -4 alkyl)amino, ⁇ iV-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, iy-(Ci.
• R 10 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, iV-(Ci -4 alkyl)amino, ⁇ N-(Ci -4 alkyl) 2 amino, TV-(C i -4 alkyl)carbamoyl, A ⁇ iV-(C 1-4 alkyi) 2 carbamoyl, Ci -4 alkylS(O) a wherein a is 0 to 2, Ci -4 alkoxycarbonyl, ⁇ iV-(Ci -4 alkyi) 2 sulphamoyl, C 1-4 alkylsulphonylamino 5 C 1-4 alkoxycarbonylamino,
• R 7 , R 11 and R 15 are independently selected from C 1-4 alkyl, C t ⁇ alkanoyl, C ⁇ alkylsulphonyl, Cmalkoxycarbonyl, carbamoyl, iV-(Ci -4 alkyl)carbamoyl, ⁇ iV-(C 1-4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
• R 8 , R 9 , R 12 and R 13 are independently selected from a direct bond, -O-, -N(R 16 )-, -C(O)-, -N(R I7 )C(0)-, -C(O)N(R 18 )-, -S(O) P -, -SO 2 N(R 19 )- or -N(R 20 )SO 2 -; wherein R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
• R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, Af-methyl-iV-ethylamino, acetylamino, N-methylcarbamoyl, iV-ethylcarbamoyl, ⁇ JV-diniethylcarbamoyl, N, JV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethy
• R 1 is selected from hydrogen, halo, or C 1-4 alkyl
• R 2 is selected from hydrogen, halo, or Ci -4 alkyl
• R 3 is selected from hydrogen, halo, or C 1-4 alkyl
• R 5 is hydrogen or C ⁇ alkyl
• Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
• R 6 is halo, carboxy, carbamoyl, iV-(C 1-4 alkoxy)carbamoyl or d ⁇ alkoxycarbonyl;
• R 7 is selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, iV-(C[. 4 alkyl)carbamoyl, ⁇ iV-(C] -4 alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; and m is 0-4; wherein the values of R 6 may be the same or different.
• R 1 is selected from hydrogen, halo, or Ci -4 alkyl
• R 2 is selected from hydrogen, halo, or C 1-4 alkyl
• R 3 is selected from hydrogen, halo, or C ⁇ alkyl; Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
• R 6 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, iV-(methoxy)carbamoyl or methoxycarbonyl;
• R 7 is selected from C 1-4 alkyl, C] -4 alkanoyl, C 1-4 alkoxycarbonyl, carbamoyl, iV-(C 1-4 alkyl)carbamoyl, ⁇ N-(Ci -4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; and m is 0 or 1.
• R 1 is selected from hydrogen, halo, or Q ⁇ alkyl
• R 2 is selected from hydrogen, halo, or C 1-4 alkyl
• R 3 is selected from hydrogen, halo, or Ci -4 alkyl; Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 7 ; and
• R 6 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, iV-(methoxy)carbamoyl or methoxycarbonyl.
• Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention.
• the present invention also comprises any two or more compounds of the Examples.
• compounds of formula (I) 5 in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I).
• the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt thereof.
• the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated): Process a) converting a compound of formula (II):
• D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.
• L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-l-yloxy.
• M is an organometallic group
• suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro.
• R a is cyano and R b is dimethy amino or diethylamino; in the presence of a base for example sodium hydroxide, in a suitable solvent for example aqueous methanol at room temperature.
• a base for example sodium hydroxide
• a suitable solvent for example aqueous methanol at room temperature.
• R a and R b are independently selected from Ci -4 alkylthio; or R a and R b together form 1 ,3-dithianyl or 1 ,3-dithiolanyl; in the presence of a reagent such as a mercury, copper or silver salt for example Hg(C10 4 ) 2 , CuCl 2 or AgNCVAg 2 O in the presence of a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.
• a reagent such as a mercury, copper or silver salt for example Hg(C10 4 ) 2 , CuCl 2 or AgNCVAg 2 O
• a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.
• Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di- ⁇ /£y/-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine.
• Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylfomiamide.
• the coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
• Compounds of formula (V) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
• Process d) Compounds of formula (VI) and (VII) may be reacted in a suitable solvent such a DCM or 1,2-dichloroethane, optionally in the presence of a Lewis acid, for example AlCl 3 , from 0 0 C to room temperature.
• a suitable solvent such as DCM or 1,2-dichloroethane
• a Lewis acid for example AlCl 3
• Suitable values for R a include Deprotection of the R a carboxy protecting group may be achieved under standard conditions, for example acid or base hydrolysis, such as those conditions give hereinbelow.
• FGI stands for Functional Group Interconversion. In the above scheme such conversions between an acid group and a -C(O)L group are well known in the art and are well within the capabilities of a person skilled in the art.
• Introduction of substituents into a ring may convert one compound of the formula (I) into another compound of the formula (I).
• Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents , oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings.
• aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group.
• modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
• the skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products.
• the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4 th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.
• a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl.
• an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
• a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.
• a suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or /-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
• the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
• an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
• a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
• an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
• a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid
• an arylmethoxycarbonyl group such as a benzyloxycarbonyl group
• a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.
• a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
• a base such as sodium hydroxide
• a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
• the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.
• an optically active form of a compound of the invention When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.
• a pure regioisomer of a compound of the invention when required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure. Enzyme Potency Testing Methods
• Assays were performed in multiwell plates in lOO ⁇ l reactions containing: 50 mM TRIS buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 16 ⁇ g/ml sheared salmon sperm DNA, 4 nM E. coli GyrA, A rM E. coli GyrB, 250 ⁇ M ATP, and compound in dimethylsulfoxide.
• Reactions were quenched with 150 ⁇ l of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium molybdate tetrahydrate, and 1 M hydrochloric acid. Plates were read in an absorbance plate reader at 625 nm and percent inhibition values were calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 ⁇ M) reactions as 100% inhibition controls.
• Compounds of the Examples generally have an IC 5O of ⁇ 20 ⁇ g/ml.
• Bacterial Susceptibility Testing Methods Compounds were tested for antimicrobial activity by susceptibility testing in liquid media. Compounds were dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay were grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism. The suspension was a 0.5 McFarland and a further 1 in 10 dilution was made into the same liquid medium to prepare the final organism suspension in 100 ⁇ L. Plates were incubated under appropriate conditions at 37 degrees C for 24 hrs prior to reading. The Minimum Inhibitory Concentration was determined as the lowest drug concentration able to reduce growth by 80% or more. Example 7 had an MIC of 1.0 ⁇ g/ml against Streptococcus pneumoniae. Other examples are provided in the following table.
• a compound of the formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
• a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.
• a method for inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
• a method of treating a bacterial infection in a warm-blooded animal which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
• a further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament.
• the medicament is an antibacterial agent.
• a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
• a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomeraselV in a warm-blooded animal such as a human being.
• a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the production of an antibacterial effect in a warm-blooded animal such as a human being.
• a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
• a compound of the formula (I) or a pharmaceutically-acceptable salt thereof for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition that comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
• a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in an warm-blooded animal, such as a human being.
• a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in an warm-blooded animal, such as a human being.
• a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in an warm-blooded animal, such as a human being.
• compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
• oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
• compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
• compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
• Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
• inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
• granulating and disintegrating agents such as corn starch or algenic acid
• binding agents such as starch
• lubricating agents
• Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
• an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
• water or an oil such as peanut oil, liquid paraffin, or olive oil.
• Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
• the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
• preservatives such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
• Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
• the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation.
• These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives.
• compositions of the invention may also be in the form of oil-in- water emulsions.
• the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
• Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as poly oxy ethylene sorbitan monooleate.
• the emulsions may also contain sweetening, flavouring and preservative agents.
• Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
• sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
• compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
• a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
• Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
• Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
• the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
• a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
• Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
• the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin).
• drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin).
• drugs for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides
• other anti-infective agents for example, an antifungal triazole or amphotericin.
• carbapenems for example meropenem or imipenem, to broaden the therapeutic effectiveness
• the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
• a daily dose in the range of 1-50 mg/kg is employed.
• the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
• compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in- vitro and in- vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase in laboratory animais such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
• temperatures are given in degrees Celsius ( 0 C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
• NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d 6 ) as solvent unless otherwise indicated;
• Benzyl 4-r2-(3.4-dichloro-5-methyl-lH " -pyrrol-2-yl)-2-oxoethyl]piperidme-l-carboxylate To a solution of benzyl 4-[2-(5-methyl-lH-pyrrol-2-yl)-2-oxoethyl]piperidine-l- carboxylate (Intermediate 3, 0.70 g, 2.05 mmol) in dichloromethane (9 ml) at 0 0 C was added iV-chlorosuccinimide (0.55 g, 4.1 mmol) all at once. The reaction mixture was allowed to warm to room temperature and was stirred for 2-3 hours.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=36916822

Family Applications (1)

Country Status (4)

Families Citing this family (12)

Family Cites Families (2)

• 2006
  • 2006-02-16 CN CNA2006800130634A patent/CN101163697A/zh active Pending
  • 2006-02-16 EP EP06709767A patent/EP1856103A2/de not_active Withdrawn
  • 2006-02-16 JP JP2007555692A patent/JP2008530192A/ja active Pending
  • 2006-02-16 WO PCT/GB2006/000530 patent/WO2006087544A2/en active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events